Questcor Pharmaceuticals (QCOR +3.7%) reports significantly higher prescription growth in August...
Questcor Pharmaceuticals (QCOR +3.7%) reports significantly higher prescription growth in August for its lead product, Acthar Gel. The company says that during the period, it shipped a total of 2,190 vials of Acthar to CuraScript SD, an increase of 33% M/M. Jefferies says the prescription data was strong and that the company will likely beat the Q3 consensus revenue estimate. The firm reiterates a Buy with a $60 price target.
From other sites
at Zacks.com (Mar 24, 2015)
at Zacks.com (Mar 6, 2015)
at Nasdaq.com (Mar 3, 2015)
at Zacks.com (Feb 27, 2015)
at Nasdaq.com (Feb 12, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs